This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rythmol IR

GlaxoSmithKline plc

Drug Names(s): Propafenone Immediate Release

Description: BioMedTracker has separate drug profiles for the SR and IR formulationsof Rythmol. Please also see Rythmol-SR.

Propafenone is a class Ic antiarrythmic agent (see below), which decrease intracardiac conduction but have a minimal effect on the duration of the electrical impulse (action potential). Class Ic agents have the most potent sodium channel blocking effects of all class I agents.

The Vaughan Williams Classification is as follows: I (blocks sodium channel; subclasses based on their effect on action potential duration), II (blocks beta-adrenergic receptors), III (blocks potassium efflux), IV (blocks L-type calcium channels, affecting conduction through the AV node between the upper and lower chambers of the heart), V (other).

Deal Structure: In November 2007, GlaxoSmithKline and Reliant Pharmaceuticals announced that they reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million) in cash. In December 2007, GlaxoSmithKline completed the acquisition of Reliant Pharmaceuticals.

Rythmol IR News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug